Atrogi’s muscle drug shows early power signal ahead of Phase 2 - European Biotechnology Magazine

Atrogi announces positive human data for ATR-258, its first-in-class, oral therapy designed to improve muscle function and body composition

In the 8-week study, ATR-258 was well-tolerated and associated with an approximately 13% mean improvement in lower extremity muscle power in combination with a beneficial effect on body composition, with an increase in lean muscle mass and a reduction in fat mass Data provide first human proof-of-mechanism and support Atrogi’s planned Phase 2 trial expected […]

Atrogi’s muscle drug shows early power signal ahead of Phase 2 - European Biotechnology Magazine

Swedish biotech Atrogi says its oral drug ATR-258 increased lower-extremity muscle power by about 13% after eight weeks in a study of 13 people with overweight or obesity. Participants also lost an average of 1.1 kg of fat mass and gained 0.8 kg of lean mass.